Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937364 | 0.89 | ALDH1A1 (0.57) | RORCALDH1A1USP2TPSAB1KDM4E | |
| SCHEMBL18701720 | 0.85 | RORC (0.49) | RORCALDH1A1USP2TPSAB1KDM4E | |
| SCHEMBL558066 | 0.82 | SCN9A (0.61) | RORCKDM4EKMT2AMEN1 | |
| SCHEMBL17067795 | 0.82 | ALDH1A1 (0.51) | ALDH1A1USP2KDM4ELMNAPOLB | |
| SCHEMBL23212047 | 0.82 | RORC (0.50) | RORCKMT2A | |
| SCHEMBL26684062 | 0.82 | DRD2 (0.47) | RORC | |
| SCHEMBL17495546 | 0.82 | RORC (0.50) | RORC | |
| SCHEMBL5201722 | 0.80 | HTR2B (0.53) | RORCALDH1A1USP2LMNAPOLB | |
| SCHEMBL28127883 | 0.79 | ALDH1A1 (0.49) | ALDH1A1USP2LMNAKMT2A | |
| SCHEMBL16244842 | 0.79 | KDM4E (0.53) | RORCUSP2TPSAB1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691807-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Astellas Pharma Inc. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050245540-A1 | New methods | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| WO-2005056012-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245540-A1 | New methods | TGFB1, TGFBR1, TGFB2 | RORC 1017/4885ALDH1A1 885/4885USP2 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.